Live-attenuated flaviviruses with heterologous antigens
AssigneeKatholieke Universiteit Leuven
InventorsRobbert Boudewijns, Kai Dallmeier, Johan Neyts
Life of this patent
Estimating the term…
Abstract
The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.
Claims43
A polynucleotide comprising a nucleotide sequence encoding a flavivirus wherein the nucleotide sequence encoding the flavivirus is preceded by a sequence encoding:
- a part of a flavivirus capsid protein comprising or consisting of an N terminal part of the flavivirus capsid protein,
- an immunogenic core antigen of hepatitis B virus (HBC), and
- a 2A cleaving peptide.
A flavivirus fusion construct comprising a flavivirus amino acid sequence wherein the flavivirus amino acid sequence is preceded at its aminoterminus by:
- a part of a flavivirus capsid protein comprising or consisting of an N terminal part of the flavivirus capsid protein,
- an immunogenic core antigen of hepatitis B virus (HBC), and
- a 2A cleaving peptide.
Dependencies are inferred from the claim text.